May 19, 2020 | Densitas Inc., News
Read original here
Mo Abdolell is CEO/Founder of Densitas Inc., a company focused on the mammography enterprise that delivers machine learning solutions for personalized breast health with technologies focused on breast density, clinical image quality, tailored risk.
Mo is also Associate Professor, Diagnostic Radiology, Dalhousie University and as a consulting biostatistician has 25 years experience in study design, statistical analysis and machine learning in biomedical/clinical research.
Densitas has also launched a program to help with radiology personnel during the COVID-19 pandemic. What is the program being offered?
In these unprecedented times, the primary focus of care is necessarily devoted to critically ill patients.
An unfortunate consequence of COVID-19 is that breast cancer screening has largely been put on hold.
Yet, even in the hardest hit regions we are seeing mammography facilities already planning to ramp up, starting with diagnostic and followed by screening mammography exam bookings. As that happens, the sheer number of patients awaiting breast screening in the coming weeks and months (rescheduled and net new) will present a monumental challenge to mammography facilities and health systems, with radiology personnel stretched thin.
It will be important to ensure that clinical image quality is maintained at the highest standard despite the stress of overloaded imaging throughput. AI automation of clinical image quality assessment, integrated in a comprehensive analytics and reporting platform, will boost MQSA inspection preparedness and will free up crucial resources for patient care. AI automation of breast density and breast cancer risk scoring and reporting will increase workflow efficiency and support tailored follow-up screening protocols.
Feb 6, 2020 | Densitas Inc., News
Halifax-based Densitas, whose software helps assess the density of breasts during mammograms, has announced that Prince Edward Island has become the second province, after Nova Scotia, to integrate its software across its screening program.
The Densitas software — named Densitas densityai — provides an automated mechanism for quantifying and recording breast tissue density, a risk factor for breast cancer in women. Dense breasts can mask cancerous cells. Dense breast tissue is also linked to higher chances of cancer.
Now, every woman who receives a screening mammogram on P.E.I. will be notified of her breast density through the company’s densityai algorithm.
“Our advanced solutions are built to solve real clinical problems and effectively support healthcare providers,” said Ryan Duggan, Director of Product Development at Densitas in a statement.
The Densitas platform comprises three different products that tackle challenges in breast cancer screening, including mammography quality, workflow efficiencies, compliance with national standards, and meeting accreditation requirements.
Feb 15, 2019 | Densitas Inc., News
Halifax-based breast imaging analytics company Densitas has announced a collaboration with TeleMammography Specialists of Decatur, Georgia, that will improve the quality of breast screening offered to more than 60,000 women annually.
TeleMammography Specialists is an international teleradiology services provider and will be the first U.S. beta user for the new densitasquality solution, the company said in a statement. The product will improve the communications and information sharing needed to meet FDA guidelines.
TeleMammography Specialists also plan to implement the recently released densitasdensity automated breast density assessment software.
“Our goal is to provide tools that reduce the documentation, process and communication burdens of meeting EQUIP (FDA) guidelines and enables sustainable delivery of quality assurance across the mammography enterprise,” Mohamed Abdolell, CEO of Densitas, said in the statement.
See full article here
